TP53 and endometrial cancer: This type of abnormality occurs in approximately 30% of endometrial cancers and is associated with a moderate prognosis—worse than in ultramutated tumors (e.g., with POLEmut) but more favorable than in aggressive subtypes with p53 mutations.